ArticleJournal of translational internal medicine2021
Clinical Challenges with Hypervirulent
Article in Journal of translational internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of hypervirulentFrontiers in medicine · 2025Pooled it
- Comparative profiling of virulence determinants, capsular serotypes, and antimicrobial resistance in hypervirulent and classical Klebsiella pneumoniae isolates from liver abscess patients.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Fitness cost of ceftazidime-avibactam resistance acquisition in carbapenem-resistant hypervirulent Klebsiella pneumoniae.BMC microbiology · 2026Article
- Overcoming phagocytosis resistance of hypervirulentMicrobial cell (Graz, Austria) · 2026Article
- Review
- Assessment of Hypervirulent Klebsiella pneumoniae Isolates Using Multilocus Sequence Typing in West of Iran.MicrobiologyOpen · 2025Article
- Article
- Phage vB_Kpn_HF0522: Isolation, Characterization, and Therapeutic Potential in Combatting K1Infection and drug resistance · 2025Article
- Capsular Polysaccharide as a Potential Target in Hypervirulent and Drug-ResistantInfection and drug resistance · 2025Review
- Mechanisms of Antimicrobial Resistance inInfection and drug resistance · 2025Review
- Pulmonary and extra-pulmonary infections caused by classical and hypervirulentFrontiers in microbiology · 2025Article
- HypervirulentPathogens & immunity · 2024Review
- Molecular characteristics and pathogenic mechanisms of KPC-3 producing hypervirulent carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Differences in molecular characteristics and expression of virulence genes in carbapenem-resistant and sensitiveFrontiers in microbiology · 2024Article
- Case report: Trauma-inducedFrontiers in medicine · 2024Article
- Gas embolism caused by gas-forming pyogenic liver abscess.Journal of translational internal medicine · 2023Article
- The Determination of Polymyxin B in Critically Ill Patients by the HPLC-MS/MS Method.International journal of analytical chemistry · 2023Article
- Epidemiological and Antimicrobial Resistant Patterns, and Molecular Mechanisms of Carbapenem-ResistantInfection and drug resistance · 2023Article
- Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-ProducingMicrobiology spectrum · 2022Article
- Molecular epidemiological characteristics of carbapenem-resistant Klebsiella pneumoniae among children in China.AMB Express · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypervirulent
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.